SCHEMBL2833252

SCHEMBL2833252

CC(C)(C)OC(=O)NC(C(=O)c1ccc(OCCC(F)(F)F)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.46
MDM2 Q00987 2/20 0.40
GABRB1 P18505 1/20 0.39
GABRB2 P47870 1/20 0.39
ACACB O00763 3/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
HRH2 P25021 4/20 0.36
HRH1 P35367 4/20 0.36
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HTRA1 Q92743 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836845 0.90 S1PR3 (0.47) S1PR3MDM2GABRB1GABRB2CTSS
SCHEMBL2834042 0.85 S1PR3 (0.48) S1PR3MDM2ACACBCTSSCTSK
SCHEMBL2835032 0.83 S1PR3 (0.46) S1PR3MDM2GABRB1GABRB2CTSS
SCHEMBL2838253 0.83 S1PR3 (0.46) S1PR3MDM2ACACBHRH2HRH1
SCHEMBL2835001 0.81 S1PR3 (0.48) S1PR3MDM2GABRB1GABRB2CTSS
SCHEMBL2832303 0.81 S1PR3 (0.49) S1PR3MDM2GABRB1GABRB2CTSS
SCHEMBL2835057 0.81 S1PR3 (0.48) S1PR3MDM2GABRB1GABRB2CTSS
SCHEMBL2833208 0.80 S1PR3 (0.45) S1PR3MDM2GABRB1GABRB2ACACB
SCHEMBL2833750 0.80 S1PR3 (0.48) S1PR3MDM2CTSSCTSKHTT
SCHEMBL2836642 0.80 S1PR3 (0.48) S1PR3MDM2GABRB1GABRB2CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MDM2 4155/4885GABRB1 536/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MDM2 4155/4885GABRB1 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.